Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19309448 | 2-DIARYLMETHYL-4-AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS AS ANTICANCER, ANTIINFLAMMATORY, ANTIFIBROTIC AND NEUROPROTECTIVE AGENTS | August 2025 | November 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18273879 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | July 2023 | January 2026 | Allow | 30 | 0 | 0 | No | No |
| 18255396 | SMALL THERAPEUTIC MOLECULES CAPABLE OF INHIBITING THE CATALYTIC ACTIVITY OF THE MAIN PROTEASE ENZYME OF SARS-COV-2 | June 2023 | March 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18039785 | TOPICAL FORMULATION COMPRISING SIROLIMUS | June 2023 | February 2026 | Allow | 32 | 1 | 0 | Yes | No |
| 18131405 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | April 2023 | March 2025 | Allow | 23 | 1 | 0 | No | No |
| 18028632 | CLASS OF 1,7-NAPHTHYRIDINE COMPOUNDS AND APPLICATION THEREOF | March 2023 | August 2025 | Abandon | 29 | 0 | 0 | No | No |
| 18188541 | METHODS FOR TREATING HYPERVIRULENT KLEBSIELLA PNEUMONIAE INFECTION | March 2023 | February 2026 | Allow | 35 | 3 | 1 | No | No |
| 18245737 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | March 2023 | March 2026 | Allow | 36 | 2 | 0 | No | No |
| 18185844 | RALINEPAG PRODRUGS AND USES THEREOF | March 2023 | January 2026 | Abandon | 34 | 2 | 1 | No | No |
| 18181231 | METHODS OF USING FTO INHIBITORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | March 2023 | February 2026 | Abandon | 35 | 2 | 1 | No | No |
| 18116625 | INHIBITORS OF THEM1 | March 2023 | March 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18018012 | METHOD FOR PREPARING FORODESINE | January 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18015880 | METHODS FOR SCREENING NOVEL CORONAVIRUS ANTIVIRALS AND METHODS OF USING ANTIVIRALS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | January 2023 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18013402 | HPK1 INHIBITORS AND USES THEREOF | December 2022 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18069622 | HETEROCYCLIC INHIBITORS OF RHO GTPases FOR THE TREATMENT OF DISEASE | December 2022 | March 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 17999275 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | November 2022 | November 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17999254 | Fused Imidazole Derivatives as AHR Antagonists | November 2022 | November 2025 | Allow | 35 | 1 | 0 | No | No |
| 17999295 | PYRIDO-PYRAZINYL COMPOUNDS FOR TREATING ACUTE MYELOID LEUKEMIA | November 2022 | February 2026 | Allow | 39 | 1 | 1 | No | No |
| 17920478 | METHOD FOR TREATING VIRAL AND BACTERIAL INFECTION THROUGH INHALATION THERAPY | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17919204 | PLEUROMUTILIN IN DERIVATIVES FOR TREATING VIRAL INFECTIONS | October 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 17917435 | SUBSTITUTED PYRAZINECARBOXAMIDE COMPOUNDS FOR TREATING DISEASES RELATED TO EGFR MUTATION | October 2022 | January 2026 | Allow | 39 | 2 | 0 | No | No |
| 17907238 | GOLD(III)-BIGUANIDE PRODRUGS, METHODS OF PREPARATION AND USES THEREOF | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17909708 | CRYSTAL OF TRICYCLIC COMPOUND ACTING ON CRBN PROTEIN AND PREPARATION METHOD THEREFOR | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17800609 | 6,7-DIMETHOXY-3-(PYRIDIN-2-YL)QUINOLINE COMPOUNDS FOR INHIBITING RET | August 2022 | November 2025 | Allow | 39 | 1 | 0 | No | No |
| 17798417 | METHODS FOR MODULATING CALORIE CONSUMPTION | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17759880 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | August 2022 | February 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17796388 | RAS INHIBITORS AND METHODS OF USING THE SAME | July 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17791364 | SMALL MOLECULE MODULATORS OF KSR-BOUND MEK | July 2022 | February 2026 | Allow | 44 | 1 | 1 | No | No |
| 17788127 | SUBSTITUTED N-(4-(PYRIMIDIN AND PYRIDIN-4-YL)BENZYLCARBOXAMIDES AND ITS USE FOR TREATING DISORDERS RESPONSIVE TO INHIBITION OF BTK | June 2022 | October 2025 | Allow | 40 | 1 | 0 | No | No |
| 17779137 | Novel compounds for treatment of diseases related to DUX4 expression | May 2022 | January 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17779055 | CHEMOTHERAPY FOR GLIOMA THROUGH NEURONAL CONVERSION | May 2022 | February 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17767744 | NEW CARBAZOLE DERIVATIVES SENSITIZING CELLS TO ANTI-CANCER AGENTS | April 2022 | May 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17638106 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | February 2022 | November 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17652022 | HETEROCYCLIC INHIBITORS OF MCT4 | February 2022 | July 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17637014 | COMBINATION THERAPY AND BIOMARKER INDICATING EFFICACY THEREOF | February 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17629546 | ANTIMYCOTIC METHOXYFLAVONE AND FLUCONAZOLE COMBINATION FOR INHIBITING CRYPTOCOCCUS | January 2022 | March 2026 | Allow | 50 | 2 | 1 | Yes | No |
| 17622267 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE | December 2021 | October 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17622522 | QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA-PK INHIBITOR | December 2021 | August 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17621555 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | December 2021 | September 2025 | Allow | 45 | 1 | 1 | No | No |
| 17621203 | COMPOUNDS FOR INHIBITING FGFR4 | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17644742 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | December 2021 | September 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17618759 | SSTR-TARGETED CONJUGATES AND FORMULATIONS THEREOF | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17617321 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | December 2021 | July 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17614854 | BENZAMIDE-SUBSTITUTED BICYCLIC IMIDAZO- AND PYRAZOLO- FUSED -PYRIDINE, -PYRIMIDE, AND -PYRIDAZINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASES | November 2021 | March 2025 | Allow | 40 | 0 | 1 | No | No |
| 17610192 | SOLID STATE FORMS OF SAGE-217 AND PROCESSES FOR PREPARATION THEREOF | November 2021 | July 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17521153 | 3-OXADIAZOLYL SUBSTITUTED PYRAZOLO[1,5,a]PYRIMIDINES FOR ROS1, NTRK, AND ALK MEDIATED DISEASES | November 2021 | May 2025 | Allow | 42 | 1 | 1 | No | No |
| 17609105 | INHIBITING USP19 | November 2021 | December 2025 | Allow | 49 | 2 | 1 | No | No |
| 17606543 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | October 2021 | March 2025 | Allow | 40 | 0 | 1 | No | No |
| 17606243 | ENTEROVIRUS INHIBITOR | October 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17604818 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17604442 | JAK1 SELECTIVE KINASE INHIBITOR | October 2021 | December 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17604719 | USE OF FULVESTRANT FOR THE THERAPEUTIC CARE OF CENTRAL CORE DISEASE | October 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17604636 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | October 2021 | June 2025 | Allow | 44 | 1 | 1 | No | No |
| 17441642 | TERPENE BASED THERAPEUTIC DEEP EUTECTIC SYSTEM, METHOD OF OBTAINING AND USES THEREOF | September 2021 | October 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17439085 | PI4-Kinase Inhibitors and Methods of Using the Same | September 2021 | May 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17426932 | QUINDOLINE COMPOUNDS AND USES THEREOF | July 2021 | August 2025 | Allow | 49 | 2 | 0 | No | No |
| 17423444 | METHODS OF TREATING TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA | July 2021 | March 2025 | Allow | 44 | 2 | 1 | No | No |
| 17421411 | DIHYDROISOQUINOLINE COMPOUND | July 2021 | May 2025 | Abandon | 47 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner REILLY, SOPHIA JANE works in Art Unit 1627 and has examined 22 patent applications in our dataset. With an allowance rate of 54.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner REILLY, SOPHIA JANE's allowance rate of 54.5% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by REILLY, SOPHIA JANE receive 1.00 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by REILLY, SOPHIA JANE is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +52.6% benefit to allowance rate for applications examined by REILLY, SOPHIA JANE. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.